Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Moluçon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P. Coudert BP, et al. Among authors: arnould l. Ann Oncol. 2006 Mar;17(3):409-14. doi: 10.1093/annonc/mdj096. Epub 2005 Dec 6. Ann Oncol. 2006. PMID: 16332965 Free article. Clinical Trial.
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy.
Guiu S, Liegard M, Favier L, van Praagh I, Largillier R, Weber B, Coeffic D, Moreau L, Priou F, Campone M, Gligorov J, Vanlemmens L, Trillet-Lenoir V, Arnould L, Coudert B. Guiu S, et al. Among authors: arnould l. Ann Oncol. 2011 Feb;22(2):321-8. doi: 10.1093/annonc/mdq397. Epub 2010 Aug 6. Ann Oncol. 2011. PMID: 20693300 Free article.
[Comparing prediction performances of 18F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after neoadjuvant chemotherapy for HER2-positive breast cancers].
Vincent L, Jankowski C, Arnould L, Coudert B, Rouzier R, Reyal F, Humbert O, Coutant C. Vincent L, et al. Among authors: arnould l. Gynecol Obstet Fertil Senol. 2020 Sep;48(9):679-686. doi: 10.1016/j.gofs.2020.03.015. Epub 2020 Mar 20. Gynecol Obstet Fertil Senol. 2020. PMID: 32205278 French.
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
Ladoire S, Mignot G, Dalban C, Chevriaux A, Arnould L, Rébé C, Apetoh L, Boidot R, Penault-Llorca F, Fumoleau P, Roché H, Spielmann M, Levy C, Lortholary A, Eichler F, Mesleard C, Bonnetain F, Ghiringhelli F. Ladoire S, et al. Among authors: arnould l. Ann Oncol. 2012 Oct;23(10):2552-2561. doi: 10.1093/annonc/mds028. Epub 2012 Mar 19. Ann Oncol. 2012. PMID: 22431701 Free article. Clinical Trial.
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching.
Le Ray I, Dabakuyo S, Crehange G, Bardou M, Arnould L, Fraisse J, Fumoleau P, Coudert B, Causeret S, Arveux P, Maingon P, Bonnetain F. Le Ray I, et al. Among authors: arnould l. Eur J Cancer. 2012 Oct;48(15):2300-10. doi: 10.1016/j.ejca.2012.03.020. Epub 2012 Apr 17. Eur J Cancer. 2012. PMID: 22513230
329 results